The FDA has approved MTAV, a groundbreaking treatment for melanoma, a potentially deadly skin cancer. Known as tumor-infiltrating lymphocyte (TIL) therapy, this innovative approach uses a patient’s own…
Melanoma’s link to sun exposure may not be as straightforward as commonly thought. While outdoor workers have higher UV exposure, studies like a European case-control study and the…
Gal Markel, MD, PhD, chief scientist and senior oncologist at Sheba Medical Center, discusses the use of fecal microbiota transplant (FMT) for melanoma patients nonresponsive to PD-1 inhibition.…
Christian U. Blank, MD, PhD, medical oncologist in the Division of Immunology at the Netherlands Cancer Institute, provides a three year update for the first clinical trial for the…
Georgina V. Long, BSc, PhD, MBBS, co-medical director of Melanoma Institute Australia (MIA), chair of Melanoma Medical Oncology and Translational Research at MIA and Royal North Shore Hospital…
Ragini R. Kudchadkar, MD, associate professor Department of Hematology and Medical Oncology, associate director of Hematology and Medical Oncology Fellowship Program – Clinical/Service at Emory University School of…
Craig L. Slingluff Jr, MD, director of surgical oncology at the Emily Couric Clinical Cancer Center at the University of Virginia, discusses the use of seviprotimut-L vaccine against…
In an interview during the 2020 OncLive® State of the Science Summit™ on Advanced Melanoma, Tracey Liebman, MD, assistant professor in the Ronald O. Perelman Department of Dermatology at the NYU…
In a study of patients with advanced melanoma treated with single-agent nivolumab or pembrolizumab, 25.8% achieved a complete response (CR). Approximately four out of five patients with advanced…
A new multicenter study hopes to ascertain whether the adjuvant implementation of personalized cancer vaccine mRNA-4157, in combination with pembrolizumab, improves recurrence-free survival (RFS) when compared with pembrolizumab…
In this interview, Omid Hamid, MD, discusses the current landscape of targeted therapies in melanoma. He shares his thoughts about immune response, triplet therapy, and soon-to-be-released data that…
Jason J. Luke, MD, FACP, an associate professor of medicine in the Division of Hematology/Oncology and director of the Cancer Immunotherapeutics Center within the Immunology and Immunotherapy Program at…
